Novacyt S.A.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Lyn Dafydd Rees
- Full Time Employees
- 216
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 131 Boulevard Carnot Le Vésinet IF France 78110
- IPO Date
- Oct 12, 2012
- Website
- novacyt.com
- Similar Companies
- Business
- Novacyt S.A. Novacyt S.A. is an international molecular diagnostics company that develops, manufactures and commercialises a broad portfolio of integrated technologies, assays and services focused on delivering genomic medicine and end-to-end workflows from sample to result across human health, animal health and environmental sectors. The company operates through three primary business segments: Clinical, offering in vitro diagnostic products in reproductive health including non-invasive prenatal testing (NIPT), cystic fibrosis and rapid aneuploidy tests, precision medicine such as the DPYD genotyping assay for chemotherapy toxicity screening, and infectious diseases like the Winterplex multiplex respiratory PCR panel; Instrumentation, featuring next-generation Ranger Technology platforms for automated DNA sample preparation and target enrichment, genesig q16/q32 and MyGo real-time quantitative PCR (qPCR) instruments, and the Co-Prep ES automated extraction system; and Research Use Only (RUO), providing high-performance qPCR assays, custom development, whole genome/exome sequencing services and workflows for life sciences, agriculture, veterinary and pharmaceutical research. Novacyt S.A. serves clinical laboratories, research institutions, global health organisations and pharmaceutical companies, with a commercial presence in over 65 countries including key markets in Europe, Asia-Pacific, the Middle East, the Americas and Africa. Founded in 2006 and headquartered in Vélizy-Villacoublay, France, the company maintains offices in the United Kingdom (Eastleigh, Manchester and Stokesley), Singapore, the United States and Canada; it lists on the London Stock Exchange AIM (NCYT) and Euronext Growth Paris (ALNOV.PA). Subsidiaries and integrated businesses include Primerdesign for qPCR kits and reagents, Yourgene Health for NIPT and precision medicine solutions, IT-IS International for PCR instrumentation, Microgen Bioproducts and Lab21 Healthcare. In recent developments, Novacyt S.A. completed the strategic acquisition of Yourgene Health in September 2023 for £16.7 million, enhancing its diagnostics scale, diversifying revenues and accelerating growth in reproductive health and Ranger Technology, with £5 million in cost synergies achieved ahead of schedule within 18 months. The company realised an additional £3 million in annualised EBITDA improvements through 2024-2025 site consolidations, including closure of IT-IS International operations, relocation of Canadian manufacturing and Primer Design facilities, alongside disposal of its Taiwanese laboratory business. Further advancements include IVDR certification for the DPYD assay in 2023 and submission for cystic fibrosis QF-PCR, launch of MagBench automated extraction for NIPT in Asia-Pacific, a co-marketing partnership with PacBio for Ranger Technology compatibility, support for a new NIPT lab in Colombia operational since October 2024, appointment of Lyn Rees as CEO and Steve Gibson as CFO in 2024, and planned launches of four new products in 2025 with £2 million additional R&D investment targeting reproductive health, precision medicine and instrumentation.
Company News
Novacyt S.A. (NVYTF) Q2 2026 Earnings Call Transcript
Novacyt S.A. (NVYTF) Shareholder/Analyst Call Prepared Remarks Transcript
Novacyt S.A. (NVYTF) Q4 2025 Earnings Call Transcript
Novacyt S.A. (NVYTF) Discusses Acquisition of Southern Cross Diagnostics and Strategic Rationale Prepared Remarks Transcript
Novacyt S.A. (NVYTF) Discusses Interim Results, Growth Strategy, and New Product Introduction Prepared Remarks Transcript
Novacyt S.A. (NVYTF) Q4 2024 Earnings Call Transcript
Novacyt S.A. (NVYTF) Q2 2024 Earnings Call Transcript
Novacyt shares drop 16% on legal settlement news
Novacyt S.A. (NVYTF) Q4 2023 Earnings Call Transcript
Novacyt S.A. (NVYTF) Q2 2023 Earnings Call Transcript
Yourgene jumps 143% on Novacyt £16.7m knock-out bid
Novacyt S.A. (NVYTF) Q4 2022 Earnings Call Transcript
Novacyt gets UK approval for seventh Covid test
Novacyt slips as CEO departs
Novacyt gains UK approval for its multiplex PCR test for detection of winter viruses
Novacyt S.A. (NVYTF) Q2 2022 Earnings Call Transcript
Novacyt receives EU approval for saliva-based Covid test
Novacyt shares slide as DHSC issues a claim against the company
Novacyt has third Covid test approved in UK
Novacyt says COVID-19 test wins UK approval, pares back revenue shortfall guidance